SUBSCRIBE
SUBSCRIBE

Nimbus Therapeutics

NEWS
Drug Development
Navitor Appoints New CEO
Navitor Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced that Thomas E. Hughes will be the company’s new chief executive officer.
August 3, 2018
 · 
3 min read
 · 
Mark Terry
Business
HotSpot Therapeutics Emerges From Stealth Mode With $45 Million to Aim at New Biological Targets
HotSpot Therapeutics burst forth from stealth mode with $45 million in Series A funding to support the development of therapies that will target natural “regulatory hotspots.”
July 17, 2018
 · 
2 min read
 · 
Alex Keown
Pictured: Pile of money/iStock, Ihor Lukianenko
Biotech Beach
Metacrine Closes $65 Million Series C Round
Metracrine, based in San Diego, completed a Series C financing round worth $65 million.
June 6, 2018
 · 
3 min read
 · 
Mark Terry
Genetown
Nimbus Therapeutics Raises Another $65 Million from Lilly, Bill Gates, Pfizer and Others
Nimbus Therapeutics, raised an additional $65 million in financing.
June 5, 2018
 · 
3 min read
 · 
Mark Terry
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Genetown
MA Life Science Growing: Backed By Eli Lilly and Pfizer, Nimbus Therapeutics Bankrolls $43 Million
March 18, 2015
 · 
2 min read
Load More
JOBS
IN THE PRESS
Business
Nimbus Therapeutics Appoints Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer
October 26, 2022
 · 
2 min read
Business
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Small Molecule Activators of AMPK
October 11, 2022
 · 
2 min read
Genetown
Nimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology
September 12, 2022
 · 
4 min read
Drug Development
Nimbus Therapeutics Presents New Data on Oral Allosteric TYK2 Inhibitor at American Chemical Society Meeting
August 24, 2022
 · 
3 min read
Drug Development
Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting
May 19, 2022
 · 
3 min read
Business
Nimbus Therapeutics Strengthens Clinical Development Leadership Team
April 13, 2022
 · 
3 min read
Genetown
Nimbus Therapeutics Presents Preclinical Data on Cbl-b Inhibitor at AACR Annual Meeting
April 8, 2022
 · 
2 min read
Drug Development
Nimbus Therapeutics to Present Update on Cbl-b Discovery Program at AACR 2022 Annual Meeting
March 28, 2022
 · 
1 min read
Drug Development
Nimbus Therapeutics Presents Clinical Data from Phase 1b Study of Oral Allosteric TYK2 Inhibitor at AAD Annual Meeting
March 25, 2022
 · 
3 min read
Genetown
Nimbus Therapeutics Shares Update on Discovery Efforts in Computational Chemistry, Expands Leadership Team
February 3, 2022
 · 
3 min read
Load More